Souhaitez-vous accéder aux communiqués récents ?

New York, USA, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics –...

Autolus announced preliminary unaudited net product revenue from sales of AUCATZYL® (obe-cel) for the fourth quarter and full year of 2025.

Autolus presented preliminary data from the Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) at ASH 2025.

Data from a Phase 1 dose confirmation clinical trial of obe-cel in severe refractory systemic lupus erythematosus will be presented.

Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and...

Autolus announces the publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025.

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activityDZP showed consistent improvements in fatigue,...

Autolus presented updates on its development pipeline and plans for expansion in autoimmune diseases at an R&D investor event.

EXTON, PA, April 10, 2025 (GLOBE NEWSWIRE) -- As treatment approaches for cutaneous lupus erythematosus (CLE) continue to evolve, new data from Spherix Global Insights shed light on how specialists...